Etoricoxib

A DHA metabolite derived via epoxidation of the 16,17-double bond epoxygenase metabolites of DHA have been detected in a mouse model of inflammation.

BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 ( IDO-1 ) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.In VitroBMS-978587 (IDO-IN-4) (Compound example 1 enantiomer 1) is a IDO-1 inhibitor in human

EtoricoxibEtoricoxib(MK-0663) selectively inhibited COX-2 in human whole blood assays in vitro, with an IC50 value of1.1 ± 0.1 μM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC50 value of 116 ± 8 μM for COX-1 (serum

A dipyridinyl compound that demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1.

A dipyridinyl compound that demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1.

Etoricoxib-d 4 is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor , with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.Form:Solid.

Etoricoxib-d 4 is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor , with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.Form:Solid.